Korean J Transplant.  2022 Mar;36(1):2-14. 10.4285/kjt.22.0008.

Cold but not too cold: advances in hypothermic and normothermic organ perfusion

• Kirste G

• KMID: 2527893
• DOI: http://doi.org/10.4285/kjt.22.0008

Abstract

Transplantation is the method of choice and, in many cases, the only method of treatment for patients with end-stage organ disease. Excellent results have been achieved, and the main focus today is to extend the number of available donors. The use of extended-criteria donors or donors after circulatory death is standard, but is accompanied by an increased risk of ischemia reperfusion injury. This review presents newly developed machine perfusion techniques using hypothermic, subnormothermic, or normothermic conditions, with or without oxygenation. Possibilities for treatment and quality assessment in decision-making about organ acceptability are also discussed.

Keyword

Organ donation; Organ protection; Cold storage; Normothermic machine perfusion; Ischemic reperfusion injury

Reference

1. Leeson S, Desai SP. 2015; Medical and ethical challenges during the first successful human kidney transplantation in 1954 at Peter Bent Brigham Hospital, Boston. Anesth Analg. 120:239–45. DOI: 10.1213/ANE.0000000000000521. PMID: 25625266.

2. Belzer FO, Ashby BS, Dunphy JE. 1967; 24-Hour and 72-hour preservation of canine kidneys. Lancet. 2:536–8. DOI: 10.1016/S0140-6736(67)90498-9. PMID: 4166894.

3. Belzer FO, Ashby BS, Gulyassy PF, Powell M. 1968; Successful seventeen-hour preservation and transplantation of human-cadaver kidney. N Engl J Med. 278:608–10. DOI: 10.1056/NEJM196803142781108. PMID: 4866541.

4. Collins GM, Bravo-Shugarman M, Terasaki PI. 1969; Kidney preservation for transportation: initial perfusion and 30 hours' ice storage. Lancet. 2:1219–22. DOI: 10.1016/S0140-6736(69)90753-3. PMID: 4187813.

5. Groenewoud AF, Buchholz B, Gubernatis F, Hölscher M, Hoyer J, Isemer F, et al. 1990; First results of the multicenter study of HTK protection for kidney transplants. Transplant Proc. 22:2212. PMID: 2219347.

6. Isemer FE, Ludwig A, Schunck O, Bretschneider HJ, Peiper HJ. 1988; Kidney procurement with the HTK solution of Bretschneider. Transplant Proc. 20:885–6. PMID: 3142122.

7. In : Eble FJ, Kirste G, editors. Single centre results of organ preservation with Eurocollins, HTK and UW solution. Proceedings of Custodiol-Symposium; 1992 Jun 29; Freiburg im Breisgau, Germany.

8. Ploeg RJ. 1990; Kidney preservation with the UW and Euro-Collins solutions: a preliminary report of a clinical comparison. Transplantation. 49:281–4. DOI: 10.1097/00007890-199002000-00011. PMID: 2407002.

9. Southard JH. Collins GM, Dubernard JM, Land W, Persijn GG, editors. 1997. Biochemistry and cell physiology of organ preservation. Procurement, preservation and allocation of vascularized organs. Springer;Dordrecht, NL: p. 103–13. DOI: 10.1007/978-94-011-5422-2_12.

10. Stewart ZA, Lonze BE, Warren DS, Dagher NN, Singer AL, Montgomery RA, et al. 2009; Histidine-tryptophan-ketoglutarate (HTK) is associated with reduced graft survival of deceased donor kidney transplants. Am J Transplant. 9:1048–54. DOI: 10.1111/j.1600-6143.2008.02545.x. PMID: 19298449.

11. Pedotti P, Cardillo M, Rigotti P, Gerunda G, Merenda R, Cillo U, et al. 2004; A comparative prospective study of two available solutions for kidney and liver preservation. Transplantation. 77:1540–5. DOI: 10.1097/01.TP.0000132278.00441.CF. PMID: 15239618.

12. Lynch RJ, Kubus J, Chenault RH, Pelletier SJ, Campbell DA, Englesbe MJ. 2008; Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin preservation in renal transplantation. Am J Transplant. 8:567–73. DOI: 10.1111/j.1600-6143.2007.02065.x. PMID: 18162093.

13. de Boer JD, Strelniece A, van Rosmalen M, de Vries E, Ysebaert D, Guba M, et al. 2018; The effect of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution: an analysis of the Eurotransplant registry. Transplantation. 102:1870–7. DOI: 10.1097/TP.0000000000002406. PMID: 30130321.

14. Groenewoud AF, Thorogood J. 1993; Current status of the Eurotransplant randomized multicenter study comparing kidney graft preservation with histidine-tryptophan-ketogluterate, University of Wisconsin, and Euro-Collins solutions. The HTK Study Group. Transplant Proc. 25(1 Pt 2):1582–5. PMID: 8442198.

15. O'Callaghan JM, Knight SR, Morgan RD, Morris PJ. 2012; Preservation solutions for static cold storage of kidney allografts: a systematic review and meta-analysis. Am J Transplant. 12:896–906. DOI: 10.1111/j.1600-6143.2011.03908.x. PMID: 22221739.

16. Opelz G, Döhler B. 2007; Multicenter analysis of kidney preservation. Transplantation. 83:247–53. DOI: 10.1097/01.tp.0000251781.36117.27. PMID: 17297393.

17. European Directorate for the Quality of Medicines and HealthCare. 2022. Guide to the quality and safety of organs for transplantation, 8th ed [Internet]. European Directorate for the Quality of Medicines and Healthcare;Strasbourg: Available from: https://www.edqm.eu. cited 2022 Mar 8.

18. Kayler LK, Srinivas TR, Schold JD. 2011; Influence of CIT-induced DGF on kidney transplant outcomes. Am J Transplant. 11:2657–64. DOI: 10.1111/j.1600-6143.2011.03817.x. PMID: 22051325.

19. Wind J, Snoeijs MG, van der Vliet JA, Winkens B, Christiaans MH, Hoitsma AJ, et al. 2011; Preservation of kidneys from controlled donors after cardiac death. Br J Surg. 98:1260–6. DOI: 10.1002/bjs.7543. PMID: 21656512.

20. Echterdiek F, Latus J, Döhler B, Schwenger V, Süsal C. 2021; Influence of cold ischemia time on the outcome of kidney transplants from donors aged 70 years and above: a collaborative transplant study report. Transplantation. 105:2461–9. DOI: 10.1097/TP.0000000000003629. PMID: 33988347.

21. Weissenbacher A, Stone JP, Lo Faro ML, Hunter JP, Ploeg RJ, Coussios CC, et al. 2022; Hemodynamics and metabolic parameters in normothermic kidney preservation are linked with donor factors, perfusate cells, and cytokines. Front Med (Lausanne). 8:801098. DOI: 10.3389/fmed.2021.801098. PMID: 35083252. PMCID: PMC8784871.

22. Fischer-Fröhlich CL, Kutschmann M, Feindt J, Schmidtmann I, Kirste G, Frühauf NR, et al. 2015; Influence of deceased donor and pretransplant recipient parameters on early overall kidney graft-survival in Germany. J Transplant. 2015:307230. DOI: 10.1155/2015/307230. PMID: 26539298. PMCID: PMC4619958.

23. Terasaki PI. 2011; Cold ischemia time: time to rethink the risk for kidneys? Am J Transplant. 11:2551–2. DOI: 10.1111/j.1600-6143.2011.03742.x. PMID: 22123279.

24. Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F, Napieralski BP, et al. 2009; Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med. 360:7–19. DOI: 10.1056/NEJMoa0802289. PMID: 19118301.

25. Moers C, Pirenne J, Paul A, Ploeg RJ. Machine Preservation Trial Study Group. 2012; Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med. 366:770–1. DOI: 10.1056/NEJMc1111038. PMID: 22356343.

26. Treckmann J, Moers C, Smits JM, Gallinat A, Maathuis MH, van Kasterop-Kutz M, et al. 2011; Machine perfusion versus cold storage for preservation of kidneys from expanded criteria donors after brain death. Transpl Int. 24:548–54. DOI: 10.1111/j.1432-2277.2011.01232.x. PMID: 21332580.

27. Smith TB, Nicholson ML, Hosgood SA. 2021; Advances in hypothermic and normothermic perfusion in kidney transplantation. Transplantology. 2:460–77. DOI: 10.3390/transplantology2040044.

28. Jochmans I, O'Callaghan JM, Pirenne J, Ploeg RJ. 2015; Hypothermic machine perfusion of kidneys retrieved from standard and high-risk donors. Transpl Int. 28:665–76. DOI: 10.1111/tri.12530. PMID: 25630347.

29. Brat A, de Vries KM, van Heurn EW, Huurman VA, de Jongh W, Leuvenink HG, et al. Hypothermic machine perfusion as a national standard preservation method for deceased donor kidneys. Transplantation. 2021; Jun. 23. [Epub]. https://doi.org/10.1097/TP.0000000000003845. DOI: 10.1097/TP.0000000000003845. PMID: 34172648.

30. Maathuis MH, Manekeller S, van der Plaats A, Leuvenink HG, Hart NA, Lier AB, et al. 2007; Improved kidney graft function after preservation using a novel hypothermic machine perfusion device. Ann Surg. 246:982–8. DOI: 10.1097/SLA.0b013e31815c4019. PMID: 18043100.

31. Watson CJ, Wells AC, Roberts RJ, Akoh JA, Friend PJ, Akyol M, et al. 2010; Cold machine perfusion versus static cold storage of kidneys donated after cardiac death: a UK multicenter randomized controlled trial. Am J Transplant. 10:1991–9. DOI: 10.1111/j.1600-6143.2010.03165.x. PMID: 20883534.

32. Ciancio G, Gaynor JJ, Sageshima J, Roth D, Kupin W, Guerra G, et al. 2012; Machine perfusion following static cold storage preservation in kidney transplantation: donor-matched pair analysis of the prognostic impact of longer pump time. Transpl Int. 25:34–40. DOI: 10.1111/j.1432-2277.2011.01364.x. PMID: 21981661.

33. Gallinat A, Efferz P, Paul A, Minor T. 2014; One or 4 h of "in-house" reconditioning by machine perfusion after cold storage improve reperfusion parameters in porcine kidneys. Transpl Int. 27:1214–9. DOI: 10.1111/tri.12393. PMID: 24977654.

34. O'Neill S, Srinivasa S, Callaghan CJ, Watson CJ, Dark JH, Fisher AJ, et al. 2020; Novel organ perfusion and preservation strategies in transplantation: where are we going in the United Kingdom? Transplantation. 104:1813–24. DOI: 10.1097/TP.0000000000003106. PMID: 31972706.

35. Weissenbacher A, Vrakas G, Nasralla D, Ceresa CD. 2019; The future of organ perfusion and re-conditioning. Transpl Int. 32:586–97. DOI: 10.1111/tri.13441. PMID: 30980772. PMCID: PMC6850430.

36. Carrel A, Lindbergh CA. 1935; The culture of whole organs. Science. 81:621–3. DOI: 10.1126/science.81.2112.621. PMID: 17733174.

37. Jochmans I, Moers C, Smits JM, Leuvenink HG, Treckmann J, Paul A, et al. 2010; Machine perfusion versus cold storage for the preservation of kidneys donated after cardiac death: a multicenter, randomized, controlled trial. Ann Surg. 252:756–64. DOI: 10.1097/SLA.0b013e3181ffc256. PMID: 21037431.

38. Hosgood SA, Brown RJ, Nicholson ML. 2021; Advances in kidney preservation techniques and their application in clinical practice. Transplantation. 105:e202–14. DOI: 10.1097/TP.0000000000003679. PMID: 33982904. PMCID: PMC8549459.

39. DiRito JR, Hosgood SA, Tietjen GT, Nicholson ML. 2018; The future of marginal kidney repair in the context of normothermic machine perfusion. Am J Transplant. 18:2400–8. DOI: 10.1111/ajt.14963. PMID: 29878499. PMCID: PMC6175453.

40. Zulpaite R, Miknevicius P, Leber B, Strupas K, Stiegler P, Schemmer P. 2021; Ex-vivo kidney machine perfusion: therapeutic potential. Front Med (Lausanne). 8:808719. DOI: 10.3389/fmed.2021.808719. PMID: 35004787. PMCID: PMC8741203.

41. Baan CC. 2019; Repairing and regenerating organs for transplantation has become a reality. Transplantation. 103:224–6. DOI: 10.1097/TP.0000000000002557. PMID: 30681647.

42. Wilms H. 1978. Renocorticale Sauerstoffversorgung und Nierendurchblutung nach autologer Nierentransplantation beim Hund (thisis). Albert Ludwigs University of Freiburg;Freiburg: DOI: 10.1097/tp.0000000000002557.

43. Minor T, Paul A, Efferz P, Wohlschlaeger J, Rauen U, Gallinat A. 2015; Kidney transplantation after oxygenated machine perfusion preservation with Custodiol-N solution. Transpl Int. 28:1102–8. DOI: 10.1111/tri.12593. PMID: 25882869.

44. Le Meur Y, Delpy E, Renard F, Hauet T, Badet L, Rerolle JP, et al. HEMO2life® improves renal function independent of cold ischemia time in kidney recipients: a comparison with a large multicenter prospective cohort study. Artif Organs. 2021; Dec. 24. [Epub]. http://doi.org/10.1111/aor.14141. DOI: 10.1111/aor.14141. PMID: 34951495.

45. Le Meur Y, Badet L, Essig M, Thierry A, Büchler M, Drouin S, et al. 2020; First-in-human use of a marine oxygen carrier (M101) for organ preservation: a safety and proof-of-principle study. Am J Transplant. 20:1729–38. DOI: 10.1111/ajt.15798. PMID: 32012441.

46. Fontes P, Lopez R, van der Plaats A, Vodovotz Y, Minervini M, Scott V, et al. 2015; Liver preservation with machine perfusion and a newly developed cell-free oxygen carrier solution under subnormothermic conditions. Am J Transplant. 15:381–94. DOI: 10.1111/ajt.12991. PMID: 25612645. PMCID: PMC5024042.

47. Opelz G. 2022. Collaborative Transplant Study [Internet]. Collaborative Transplant Study;Heidelberg: Available from: https://www.ctstransplant.org/. cited 2022 Mar 8.

48. Feng S. 2010; Donor intervention and organ preservation: where is the science and what are the obstacles? Am J Transplant. 10:1155–62. DOI: 10.1111/j.1600-6143.2010.03100.x. PMID: 20420628.

49. de Vries EE, Hoogland ER, Winkens B, Snoeijs MG, van Heurn LW. 2011; Renovascular resistance of machine-perfused DCD kidneys is associated with primary nonfunction. Am J Transplant. 11:2685–91. DOI: 10.1111/j.1600-6143.2011.03755.x. PMID: 21967629.

50. Guy AJ, Nath J, Cobbold M, Ludwig C, Tennant DA, Inston NG, et al. 2015; Metabolomic analysis of perfusate during hypothermic machine perfusion of human cadaveric kidneys. Transplantation. 99:754–9. DOI: 10.1097/TP.0000000000000398. PMID: 25222017.

51. Moers C, Varnav OC, van Heurn E, Jochmans I, Kirste GR, Rahmel A, et al. 2010; The value of machine perfusion perfusate biomarkers for predicting kidney transplant outcome. Transplantation. 90:966–73. DOI: 10.1097/TP.0b013e3181f5c40c. PMID: 20861807.

52. Parikh CR, Hall IE, Bhangoo RS, Ficek J, Abt PL, Thiessen-Philbrook H, et al. 2016; Associations of perfusate biomarkers and pump parameters with delayed graft function and deceased donor kidney allograft function. Am J Transplant. 16:1526–39. DOI: 10.1111/ajt.13655. PMID: 26695524. PMCID: PMC4844819.

53. Niekisch MB, Von Elverfeldt D, El Saman A, Hennig J, Kirste G. 2004; Improved pretransplant assessment of renal quality by means of phosphorus-31 magnetic resonance spectroscopy using chemical shift imaging. Transplantation. 77:1041–5. DOI: 10.1097/01.TP.0000120537.69074.5D. PMID: 15087769.

54. Bon D, Billault C, Thuillier R, Hebrard W, Boildieu N, Celhay O, et al. 2014; Analysis of perfusates during hypothermic machine perfusion by NMR spectroscopy: a potential tool for predicting kidney graft outcome. Transplantation. 97:810–6. DOI: 10.1097/TP.0000000000000046. PMID: 24681441.

55. Thuillier R, Allain G, Celhay O, Hebrard W, Barrou B, Badet L, et al. 2013; Benefits of active oxygenation during hypothermic machine perfusion of kidneys in a preclinical model of deceased after cardiac death donors. J Surg Res. 184:1174–81. DOI: 10.1016/j.jss.2013.04.071. PMID: 23731682.

56. Weissenbacher A, Lo Faro L, Boubriak O, Soares MF, Roberts IS, Hunter JP, et al. 2019; Twenty-four-hour normothermic perfusion of discarded human kidneys with urine recirculation. Am J Transplant. 19:178–92. DOI: 10.1111/ajt.14932. PMID: 29758129. PMCID: PMC6491986.

57. Kaths JM, Hamar M, Echeverri J, Linares I, Urbanellis P, Cen JY, et al. 2018; Normothermic ex vivo kidney perfusion for graft quality assessment prior to transplantation. Am J Transplant. 18:580–9. DOI: 10.1111/ajt.14491. PMID: 28889600.

58. Kaths JM, Cen JY, Chun YM, Echeverri J, Linares I, Ganesh S, et al. 2017; Continuous normothermic ex vivo kidney perfusion is superior to brief normothermic perfusion following static cold storage in donation after circulatory death pig kidney transplantation. Am J Transplant. 17:957–69. DOI: 10.1111/ajt.14059. PMID: 27647696.

59. Kron P, Schlegel A, Muller X, Gaspert A, Clavien PA, Dutkowski P. 2019; Hypothermic oxygenated perfusion: a simple and effective method to modulate the immune response in kidney transplantation. Transplantation. 103:e128–36. DOI: 10.1097/TP.0000000000002634. PMID: 30747849.

60. Consortium for Organ Preservation in Europe (COPE). 2019. COPE trials [Internet]. COPE;Oxford: Available from: https://cope-eu.com/work%20programme/trials. cited 2022 Mar 7.

61. van Leeuwen LL, Leuvenink HG, Olinga P, Ruigrok MJ. 2022; Shifting paradigms for suppressing fibrosis in kidney transplants: supplementing perfusion solutions with anti-fibrotic drugs. Front Med (Lausanne). 8:806774. DOI: 10.3389/fmed.2021.806774. PMID: 35083254. PMCID: PMC8784659.

62. Hamelink TL, Ogurlu B, De Beule J, Lantinga VA, Pool MB, Venema LH, et al. 2022; Renal normothermic machine perfusion: the road toward clinical implementation of a promising pretransplant organ assessment tool. Transplantation. 106:268–79. DOI: 10.1097/TP.0000000000003817. PMID: 33979315.

63. Manara A, Shemie SD, Large S, Healey A, Baker A, Badiwala M, et al. 2020; Maintaining the permanence principle for death during in situ normothermic regional perfusion for donation after circulatory death organ recovery: a United Kingdom and Canadian proposal. Am J Transplant. 20:2017–25. DOI: 10.1111/ajt.15775. PMID: 31922653. PMCID: PMC7540256.

64. Domínguez-Gil B, Ascher N, Capron AM, Gardiner D, Manara AR, Bernat JL, et al. 2021; Expanding controlled donation after the circulatory determination of death: statement from an international collaborative. Intensive Care Med. 47:265–81. DOI: 10.1007/s00134-020-06341-7. PMID: 33635355. PMCID: PMC7907666.

65. Dalsgaard FF, Moeslund N, Zhang ZL, Pedersen M, Qerama E, Beniczky S, et al. Clamping of the aortic arch vessels during normothermic regional perfusion after circulatory death prevents the return of brain activity in a porcine model. Transplantation. 2022; Jan. 18. [Epub]. https://doi.org/10.1097/TP.0000000000004047. DOI: 10.1097/TP.0000000000004047. PMID: 35066546.

66. Shemie SD, Gardiner D. 2018; Circulatory arrest, brain arrest and death determination. Front Cardiovasc Med. 5:15. DOI: 10.3389/fcvm.2018.00015. PMID: 29662882. PMCID: PMC5890102.

67. Oniscu GC, Randle LV, Muiesan P, Butler AJ, Currie IS, Perera MT, et al. 2014; In situ normothermic regional perfusion for controlled donation after circulatory death: the United Kingdom experience. Am J Transplant. 14:2846–54. DOI: 10.1111/ajt.12927. PMID: 25283987.

68. Watson CJ, Hunt F, Messer S, Currie I, Large S, Sutherland A, et al. 2019; In situ normothermic perfusion of livers in controlled circulatory death donation may prevent ischemic cholangiopathy and improve graft survival. Am J Transplant. 19:1745–58. DOI: 10.1111/ajt.15241. PMID: 30589499.

69. Nasralla D, Coussios CC, Mergental H, Akhtar MZ, Butler AJ, Ceresa CD, et al. 2018; A randomized trial of normothermic preservation in liver transplantation. Nature. 557:50–6. DOI: 10.1038/s41586-018-0047-9. PMID: 29670285.

70. Markmann JF, Abouljoud MS, Ghobrial RM, Bhati CS, Pelletier SJ, Lu AD, et al. 2022; Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant: the OCS Liver PROTECT randomized clinical trial. JAMA Surg. 157:189–98. DOI: 10.1001/jamasurg.2021.6781. PMID: 34985503. PMCID: PMC8733869.

71. op den Dries S, Karimian N, Sutton ME, Westerkamp AC, Nijsten MW, Gouw AS, et al. 2013; Ex vivo normothermic machine perfusion and viability testing of discarded human donor livers. Am J Transplant. 13:1327–35. DOI: 10.1111/ajt.12187. PMID: 23463950.

72. Mergental H, Laing RW, Kirkham AJ, Perera MT, Boteon YL, Attard J, et al. 2020; Transplantation of discarded livers following viability testing with normothermic machine perfusion. Nat Commun. 11:2939. DOI: 10.1038/s41467-020-16251-3. PMID: 32546694. PMCID: PMC7298000.

73. Minor T, Efferz P, Fox M, Wohlschlaeger J, Lüer B. 2013; Controlled oxygenated rewarming of cold stored liver grafts by thermally graduated machine perfusion prior to reperfusion. Am J Transplant. 13:1450–60. DOI: 10.1111/ajt.12235. PMID: 23617781.

74. Watson CJ, Kosmoliaptsis V, Randle LV, Russell NK, Griffiths WJ, Davies S, et al. 2016; Preimplant normothermic liver perfusion of a suboptimal liver donated after circulatory death. Am J Transplant. 16:353–7. DOI: 10.1111/ajt.13448. PMID: 26393945.

75. Laing RW, Mergental H, Yap C, Kirkham A, Whilku M, Barton D, et al. 2017; Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial. BMJ Open. 7:e017733. DOI: 10.1136/bmjopen-2017-017733. PMID: 29183928. PMCID: PMC5719273.

76. Jamieson RW, Zilvetti M, Roy D, Hughes D, Morovat A, Coussios CC, et al. 2011; Hepatic steatosis and normothermic perfusion-preliminary experiments in a porcine model. Transplantation. 92:289–95. DOI: 10.1097/TP.0b013e318223d817. PMID: 21681143.

77. Fondevila C, Hessheimer AJ, Maathuis MH, Muñoz J, Taurá P, Calatayud D, et al. 2012; Hypothermic oxygenated machine perfusion in porcine donation after circulatory determination of death liver transplant. Transplantation. 94:22–9. DOI: 10.1097/TP.0b013e31825774d7. PMID: 22691959.

78. Op den Dries S, Sutton ME, Karimian N, de Boer MT, Wiersema-Buist J, Gouw AS, et al. 2014; Hypothermic oxygenated machine perfusion prevents arteriolonecrosis of the peribiliary plexus in pig livers donated after circulatory death. PLoS One. 9:e88521. DOI: 10.1371/journal.pone.0088521. PMID: 24551114. PMCID: PMC3925142.

79. Liu Q, Nassar A, Buccini L, Iuppa G, Soliman B, Pezzati D, et al. 2018; Lipid metabolism and functional assessment of discarded human livers with steatosis undergoing 24 hours of normothermic machine perfusion. Liver Transpl. 24:233–45. DOI: 10.1002/lt.24972. PMID: 29125712.

80. Ben Mosbah I, Roselló-Catafau J, Franco-Gou R, Abdennebi HB, Saidane D, Ramella-Virieux S, et al. 2006; Preservation of steatotic livers in IGL-1 solution. Liver Transpl. 12:1215–23. DOI: 10.1002/lt.20788. PMID: 16724331.

81. van Rijn R, Schurink IJ, de Vries Y, van den Berg AP, Cortes Cerisuelo M, Darwish Murad S, et al. 2021; Hypothermic machine perfusion in liver transplantation: a randomized trial. N Engl J Med. 384:1391–401. DOI: 10.1056/NEJMoa2031532. PMID: 33626248.

82. Dutkowski P, Schlegel A, de Oliveira M, Müllhaupt B, Neff F, Clavien PA. 2014; HOPE for human liver grafts obtained from donors after cardiac death. J Hepatol. 60:765–72. DOI: 10.1016/j.jhep.2013.11.023. PMID: 24295869.

83. Schlegel A, Dutkowski P. 2015; Role of hypothermic machine perfusion in liver transplantation. Transpl Int. 28:677–89. DOI: 10.1111/tri.12354. PMID: 24852621.

84. Fondevila C, Hessheimer AJ, Maathuis MH, Muñoz J, Taurá P, Calatayud D, et al. 2011; Superior preservation of DCD livers with continuous normothermic perfusion. Ann Surg. 254:1000–7. DOI: 10.1097/SLA.0b013e31822b8b2f. PMID: 21862925.

85. Weeder PD, van Rijn R, Porte RJ. 2015; Machine perfusion in liver transplantation as a tool to prevent non-anastomotic biliary strictures: rationale, current evidence and future directions. J Hepatol. 63:265–75. DOI: 10.1016/j.jhep.2015.03.008. PMID: 25770660.

86. Bruinsma BG, Yeh H, Ozer S, Martins PN, Farmer A, Wu W, et al. 2014; Subnormothermic machine perfusion for ex vivo preservation and recovery of the human liver for transplantation. Am J Transplant. 14:1400–9. DOI: 10.1111/ajt.12727. PMID: 24758155. PMCID: PMC4470578.

87. Kollmann D, Linares-Cervantes I, Ganesh S, Rosales R, Hamar M, Goto T, et al. 2020; Normothermic ex vivo liver perfusion prevents intrahepatic platelet sequestration after liver transplantation. Transplantation. 104:1177–86. DOI: 10.1097/TP.0000000000003194. PMID: 32091485.

88. Mabrut JY, Lesurtel M, Muller X, Dubois R, Ducerf C, Rossignol G, et al. 2021; Ex vivo liver splitting and hypothermic oxygenated machine perfusion: technical refinements of a promising preservation strategy in split liver transplantation. Transplantation. 105:e89–90. DOI: 10.1097/TP.0000000000003775. PMID: 34291769.

89. Gilbo N, Fieuws S, Meurisse N, Nevens F, van der Merwe S, Laleman W, et al. 2021; Donor hepatectomy and implantation time are associated with early complications after liver transplantation: a single-center retrospective study. Transplantation. 105:1030–8. DOI: 10.1097/TP.0000000000003335. PMID: 33052640.

90. Gilbo N, Fieuws S, Jochmans I, Monbaliu D. 2022; Reply to: "The Impact of donor hepatectomy time on liver transplantation outcomes". Transplantation. 106:e175–6. DOI: 10.1097/TP.0000000000003912. PMID: 35100233.

91. Hamaoui K, Gowers S, Sandhu B, Vallant N, Cook T, Boutelle M, et al. 2018; Development of pancreatic machine perfusion: translational steps from porcine to human models. J Surg Res. 223:263–74. DOI: 10.1016/j.jss.2017.11.052. PMID: 29325720.

92. Branchereau J, Renaudin K, Kervella D, Bernadet S, Karam G, Blancho G, et al. 2018; Hypothermic pulsatile perfusion of human pancreas: preliminary technical feasibility study based on histology. Cryobiology. 85:56–62. DOI: 10.1016/j.cryobiol.2018.10.002. PMID: 30292812.

93. Barlow AD, Hamed MO, Mallon DH, Brais RJ, Gribble FM, Scott MA, et al. 2015; Use of ex vivo normothermic perfusion for quality assessment of discarded human donor pancreases. Am J Transplant. 15:2475–82. DOI: 10.1111/ajt.13303. PMID: 25989187. PMCID: PMC7212093.

94. Fridell JA, Mangus RS, Powelson JA. 2010; Histidine-tryptophan-ketoglutarate for pancreas allograft preservation: the Indiana University experience. Am J Transplant. 10:1284–9. DOI: 10.1111/j.1600-6143.2010.03095.x. PMID: 20353471.

95. Hamed A, Tsui S, Huber J, Lin R, Poggio EC, Ardehali A. 2009; Serum lactate is a highly sensitive and specific predictor of post cardiac transplant outcomes using the organ care system. J Heart Lung Transplant. 28:S71. DOI: 10.1016/j.healun.2008.11.025.

96. Yeter R, Hübler M, Pasic M, Hetzer R, Knosalla C. 2011; Organ preservation with the organ care system. Appl Cardiopulm Pathophysiol. 15:202–12.

97. Tenderich G, Tsui S, El-Banayosy A, Dhital K, Schulte-Eistrup S, Schulz U, et al. 2008; The 1-year follow-up results of the PROTECT patient population using the organ care system. J Heart Lung Transplant. 27:S166. DOI: 10.1016/j.healun.2007.11.302.

98. García Sáez D, Zych B, Sabashnikov A, Bowles CT, De Robertis F, Mohite PN, et al. 2014; Evaluation of the organ care system in heart transplantation with an adverse donor/recipient profile. Ann Thorac Surg. 98:2099–105. DOI: 10.1016/j.athoracsur.2014.06.098. PMID: 25443013.

99. Schroder JN, D'Alessandro D, Esmailian F, Boeve T, Tang P, Liao K, et al. 2019; Successful utilization of extended criteria donor (ECD) hearts for transplantation - results of the OCS™ heart EXPAND trial to evaluate the effectiveness and safety of the OCS heart system to preserve and assess ECD hearts for transplantation. J Heart Lung Transplant. 38:S42. DOI: 10.1016/j.healun.2019.01.088.

100. Rojas SV, Ius F, Schibilsky D, Kaufeld T, Sommer W, Benk C, et al. 2019; Cardiac transplantation in higher risk patients: is ex vivo heart perfusion a safe preservation technique? A two center experience. J Heart Lung Transplant. 38:S43. DOI: 10.1016/j.healun.2019.01.091.

101. Messer S, Page A, Berman M, Colah S, Dunning J, Pavlushkov E, et al. 2019; First to 50: early outcomes following heart transplantation at Royal Papworth Hospital from donation after circulatory determined death (DCD) donors. J Heart Lung Transplant. 38:S43. DOI: 10.1016/j.healun.2019.01.090.

102. Iyer A, Gao L, Doyle A, Rao P, Cropper JR, Soto C, et al. 2015; Normothermic ex vivo perfusion provides superior organ preservation and enables viability assessment of hearts from DCD donors. Am J Transplant. 15:371–80. DOI: 10.1111/ajt.12994. PMID: 25612491.

103. Iyer A, Gao L, Doyle A, Rao P, Jayewardene D, Wan B, et al. 2014; Increasing the tolerance of DCD hearts to warm ischemia by pharmacological postconditioning. Am J Transplant. 14:1744–52. DOI: 10.1111/ajt.12782. PMID: 25040306.

104. Feizpour CA, Gauntt K, Patel MS, Carrico B, Vagefi PA, Klassen D, et al. The impact of machine perfusion of the heart on warm ischemia time and organ yield in donation after circulatory death. Am J Transplant. 2022; Jan. 10. [Epub]. https://doi.org/10.1111/ajt.16952. DOI: 10.1111/ajt.16952. PMID: 35007385.

105. Tenderich G, El-Banayosy A, Rosengard B, Tsui S, Wallwork J, Hetzer R, et al. 2007; Prospective multi-center European trial to evaluate the safety and performance of the Organ Care System for heart transplants (PROTECT). J Heart Lung Transplant. 26:S64. DOI: 10.1016/j.healun.2006.11.024.

106. McCurry K, Jeevanandam V, Mihaljevic T, Couper G, Elanwar M, Saleh H, et al. 2008; Prospective Multi-Center Safety and Effectiveness Evaluation of the Organ Care System Device for Cardiac Use (PROCEED). J Heart Lung Transplant. 27:S166. DOI: 10.1016/j.healun.2007.11.303.

107. Stamp NL, Shah A, Vincent V, Wright B, Wood C, Pavey W, et al. 2015; Successful heart transplant after ten hours out-of-body time using the TransMedics Organ Care System. Heart Lung Circ. 24:611–3. DOI: 10.1016/j.hlc.2015.01.005. PMID: 25697385.

108. de Perrot M, Liu M, Waddell TK, Keshavjee S. 2003; Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med. 167:490–511. DOI: 10.1164/rccm.200207-670SO. PMID: 12588712.

109. Loor G, Warnecke G, Villavicencio MA, Smith MA, Kukreja J, Ardehali A, et al. 2019; Portable normothermic ex-vivo lung perfusion, ventilation, and functional assessment with the Organ Care System on donor lung use for transplantation from extended-criteria donors (EXPAND): a single-arm, pivotal trial. Lancet Respir Med. 7:975–84. DOI: 10.1016/S2213-2600(19)30200-0. PMID: 31378427.

110. Mohite PN, Sabashnikov A, García Sáez D, Pates B, Zeriouh M, De Robertis F, et al. 2015; Utilization of the Organ Care System Lung for the assessment of lungs from a donor after cardiac death (DCD) before bilateral transplantation. Perfusion. 30:427–30. DOI: 10.1177/0267659114557186. PMID: 25332197.

111. Bozso S, Vasanthan V, Luc JG, Kinaschuk K, Freed D, Nagendran J. 2015; Lung transplantation from donors after circulatory death using portable ex vivo lung perfusion. Can Respir J. 22:47–51. DOI: 10.1155/2015/357498. PMID: 25379654. PMCID: PMC4324525.

112. de Vries RJ, Tessier SN, Banik PD, Nagpal S, Cronin SEJ, Ozer S, et al. 2019; Supercooling extends preservation time of human livers. Nat Biotechnol. 37:1131–6. DOI: 10.1038/s41587-019-0223-y. PMID: 31501557. PMCID: PMC6776681.